Latest news with #RaceOncology
Herald Sun
02-05-2025
- Business
- Herald Sun
Race Oncology doses first patient in RC220 Phase 1 solid tumour trial
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. First patient dosed at lead trial site, Southside Cancer Care. Phase 1 trial to determine safety, tolerability and pharmacokinetic data, plus maximum tolerated combined dose of RC220 with chemotherapeutic doxorubicin. Up to 33 patients to be recruited in first stage across sites in Australia, Hong Kong and South Korea. Special Report: The first site in Race Oncology's Phase 1 clinical trial of RC220 in advanced solid tumours has been activated with the first patient dosed safely at Southside Cancer Care Centre in Miranda, NSW. No vein inflammation or any other adverse events were reported, clearing the way for Race Oncology (ASX:RAC) to dose more patients in this first stage of the trial. The company's goal is to establish the safety, tolerability and pharmacokinetic data – in other words, the way the drug is absorbed, distributed, metabolised and excreted – as well as the maximum tolerated combined dose of RC220 in combination with powerful chemotherapy drug doxorubicin. A second trial site at the Gosford and Wyong hospitals also recently opened for patient enrolment, with up to another 32 patients to be enrolled at sites across Australia, Hong Kong and South Korea. Race Oncology CEO Dr Daniel Tillet said the safe dosing of this first patient was a major milestone for the company, and the beginning of an important program that would assess the safety, tolerability and therapeutic potential of RC220. 'We are grateful to all the patients, investigators and clinical teams who have made this trial possible,' Tillet said. 'I would also like to thank our shareholders for their strong and loyal support that has enabled us to bring RC220 to patients in the clinic." Why combine chemotherapy with RC220? RC220 is a small molecule drug found to enhance the cancer-killing activity of chemotherapy doxorubicin in 85% of 143 cancer cell lines screened by RAC. The drug has been investigated in more than 50 clinical trials where it was found to have an effect in a range of solid and blood-based cancers including breast, ovarian, kidney, lung and various leukaemias including acute myeloid leukaemia. Importantly, RC220 demonstrates an anti-cancer effect with less cardiotoxicity compared to chemotherapy anthracyclines like doxorubicin, therefore offering a potential cardioprotective effect that could reduce damage to the heart during chemotherapy treatments, while enhancing the drugs' cancer killing effect. In Stage 2 of the trial, RAC will use an optimal dosage of RC220 in combination with doxorubicin – determined by an analysis of Phase 1 data – in 20 additional patients to establish further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. As the trial is open-label, patient outcomes will be available for assessment as soon as treatment is complete. RAC intends to announce progress updated on a regular basis, but not on an individual patient level. This article was developed in collaboration with Race Oncology, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Race Oncology doses first patient in RC220 Phase 1 solid tumour trial
Yahoo
09-03-2025
- Business
- Yahoo
Race Oncology's (ASX:RAC) investors will be pleased with their stellar 240% return over the last five years
Race Oncology Limited (ASX:RAC) shareholders might be concerned after seeing the share price drop 25% in the last quarter. But that scarcely detracts from the really solid long term returns generated by the company over five years. We think most investors would be happy with the 240% return, over that period. So while it's never fun to see a share price fall, it's important to look at a longer time horizon. Only time will tell if there is still too much optimism currently reflected in the share price. While the returns over the last 5 years have been good, we do feel sorry for those shareholders who haven't held shares that long, because the share price is down 60% in the last three years. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. View our latest analysis for Race Oncology Race Oncology wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings. For the last half decade, Race Oncology can boast revenue growth at a rate of 59% per year. Even measured against other revenue-focussed companies, that's a good result. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 28% per year, compound, during the period. So it seems likely that buyers have paid attention to the strong revenue growth. Race Oncology seems like a high growth stock - so growth investors might want to add it to their watchlist. The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers). This free interactive report on Race Oncology's balance sheet strength is a great place to start, if you want to investigate the stock further. Investors in Race Oncology had a tough year, with a total loss of 6.2%, against a market gain of about 3.7%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 28% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Race Oncology better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Race Oncology (at least 1 which is concerning) , and understanding them should be part of your investment process. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
